Neuromelanin Imaging in Parkinson Disease

  • Makoto SasakiEmail author
  • Fumio Yamashita
  • Kohsuke Kudo
Part of the Current Clinical Neurology book series (CCNEU, volume 44)


Neuromelanin, a black pigment present in dopaminergic and noradrenergic neurons in the substantia nigra pars compacta (SNc) and locus ceruleus (LC), has paramagnetic T1-shortening effects. Conventional magnetic resonance imaging (cMRI) techniques fail to depict the contrast generated by neuromelanin, but there are some neuromelanin-sensitive techniques that allow direct visualization of the SNc and LC as evident high-signal areas. In Parkinson disease, neuromelanin-related signals from the SNc and LC are attenuated suggesting neuronal loss in both these nuclei. In other neurodegenerative and psychiatric disorders, signal alterations of SNc and/or LC can also be shown. Neuromelanin-sensitive MRI is a promising technique to assess changes in these nuclei that occur in Parkinson disease and other related disorders.


Parkinson Disease Multiple System Atrophy Progressive Supranuclear Palsy Progressive Supranuclear Palsy Conventional Magnetic Resonance Imaging 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was partly supported by a grant-in-aid for Advanced Medical Science Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.


  1. 1.
    Sasaki M, Shibata E, Tohyama K, et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson’s disease. Neuroreport. 2006;31:1215–8.CrossRefGoogle Scholar
  2. 2.
    Schwarz ST, Rittman T, Gontu V, et al. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson’s disease. Mov Disord. 2011;26:1633–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Nakane T, Nihashi T, Kawai H, et al. Visualization of neuromelanin in the substantia nigra and locus ceruleus at 1.5 T using a 3D-gradient echo sequence with magnetization transfer contrast. Magn Reson Med Sci. 2008;7:205–21.PubMedCrossRefGoogle Scholar
  4. 4.
    Fedorow H, Tribl F, Halliday G, et al. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson’s disease. Prog Neurobiol. 2005;75:109–24.PubMedCrossRefGoogle Scholar
  5. 5.
    Zecca L, Tampellini D, Gerlach M, et al. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol Path. 2001;54:414–8.Google Scholar
  6. 6.
    Zecca L, Zucca FA, Wilms H, et al. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci. 2003;26:578–80.PubMedCrossRefGoogle Scholar
  7. 7.
    Fasano M, Bergamasco B, Lopiano L. Modifications of the iron-neuromelanin system in Parkinson’s disease. J Neurochem. 2006;96:909–16.PubMedCrossRefGoogle Scholar
  8. 8.
    Tosk JM, Holshouser BA, Aloia RC, et al. Effects of the interaction between ferric iron and L-dopa melanin on T1 and T2 relaxation times determined by magnetic resonance imaging. Magn Reson Med. 1992;26:40–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Enochs WS, Petherick P, Boqdanova A, et al. Paramagnetic metal scavenging by melanin: MR imaging. Radiology. 1997;204:417–23.PubMedGoogle Scholar
  10. 10.
    Shibata E, Sasaki M. Imaging of neuromelanin. In: Naidich TP, Duvernoy HM, Delman BN, et al. editors. Duvernoy’s atlas of the human brain stem and cerebellum. Wien, Springer; 2009. p. 475–482.Google Scholar
  11. 11.
    Sasaki M, Shibata E, Tohyama K, et al. Monoamine neurons in the human brain stem: anatomy, magnetic resonance imaging findings, and clinical implications. Neuroreport. 2008;19:1649–54.PubMedCrossRefGoogle Scholar
  12. 12.
    Shibata E, Sasaki M, Tohyama K, et al. Reduced signal of locus ceruleus in depression in quantitative neuromelanin magnetic resonance imaging. Neuroreport. 2007;18:415–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Lehericy S, Sharman MA, Santos CL, et al. Magnetic resonance imaging of the substantia nigra in Parkinson’s disease. Mov Disord. 2012;27:822–30.PubMedCrossRefGoogle Scholar
  14. 14.
    Kashihara K, Shinya T, Higaki F. Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD. Intern Med. 2011;50:1683–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Kashihara K, Shinya T, Higaki F. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson’s disease. J Clin Neurosci. 2011;18:1093–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Shibata E, Sasaki M, Tohyama K, et al. Use of neuromelanin-sensitive MRI to distinguish schizophrenic and depressive patients and healthy individuals based on signal alterations in the substantia nigra and locus ceruleus. Biol Psychiatry. 2008;64:401–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Sasaki M, Shibata E, Ohtsuka K, et al. Visual discrimination among patients with depression and schizophrenia and healthy individuals using semiquantitative color-coded fast spin-echo T1-weighted magnetic resonance imaging. Neuroradiology. 2010;52:83–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of Ultrahigh Field MRI, Institute for Biomedical SciencesIwate Medical UniversityMoriokaJapan

Personalised recommendations